PMID- 34185197
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20220218
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 22
IP  - 8
DP  - 2021 Jun 29
TI  - Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine 
      Tumours.
PG  - 73
LID - 10.1007/s11864-021-00863-y [doi]
AB  - Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with 
      rising incidence and prevalence. Outcome and therapy of small bowel 
      neuroendocrine tumours (SBNETs) is variable, depending on the grade, 
      differentiation, tumour burden, as well as the site of the tumour origin. Because 
      of this, multidisciplinary approach is essential. Large randomized clinical 
      trials, with somatostatin analogues (PROMID, CLARINET) or with peptide receptor 
      radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial) as well as the 
      mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials), 
      represent milestones for the medical management of unresectable grade 1 and 2 
      SBNETS over the last decade. Novel therapies, such as tyrosine kinase inhibitors 
      (TKI), are on the cutting edge. However, multiple unsolved questions remain. This 
      review provides a comprehensive review of the main systemic therapeutic options 
      for advanced SBNETs and discusses the latest guideline recommendations for 
      palliative treatment.
FAU - Dawod, Mohammed
AU  - Dawod M
AUID- ORCID: 0000-0002-4980-1883
AD  - Department of Medical Oncology, ENETs, Centre of Excellence, The Christie NHS 
      Foundation Trust, Manchester, UK.
FAU - Gordoa, Teresa Alonso
AU  - Gordoa TA
AD  - Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, 
      Spain.
FAU - Cives, Mauro
AU  - Cives M
AD  - Department of Medical Oncology, University of Bari, Bari, Italy.
FAU - De Mestier, Louis
AU  - De Mestier L
AD  - Department of Gastroenterology, Beaujon Hospital, Universite de Paris, Clichy, 
      France.
FAU - Crona, Joakim
AU  - Crona J
AD  - Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
FAU - Spada, Francesca
AU  - Spada F
AD  - Gastrointestinal Medical Oncology and Neuroendocrine Tumors Unit, European 
      Institute of Oncology, Milan, Italy.
FAU - Oberg, Kjel
AU  - Oberg K
AD  - Department of Endocrinology, Universitatsklinikum Erlangen, Erlangen, Germany.
FAU - Pavel, Marianne
AU  - Pavel M
AD  - Department of Medical Oncology, ENETs, Centre of Excellence, The Christie NHS 
      Foundation Trust, Division of Cancer Sciences, University of Manchester, 
      Manchester, UK.
FAU - Lamarca, Angela
AU  - Lamarca A
AD  - The Christie NHS Foundation Trust, Wilmslow Road, M20 4BX, Manchester, UK. 
      angela.lamarca@nhs.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210629
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 51110-01-1 (Somatostatin)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Everolimus/therapeutic use
MH  - Humans
MH  - Intestinal Neoplasms/*drug therapy
MH  - Intestine, Small
MH  - Neuroendocrine Tumors/*drug therapy
MH  - Palliative Care
MH  - Practice Guidelines as Topic
MH  - Somatostatin/therapeutic use
OTO - NOTNLM
OT  - PRRT
OT  - Progression
OT  - Small bowel neuroendocrine tumour
OT  - Somatostatin analogue
OT  - Third-line treatment
OT  - Well-differentiated
EDAT- 2021/06/30 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/06/29 12:22
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/06/29 12:22 [entrez]
PHST- 2021/06/30 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
AID - 10.1007/s11864-021-00863-y [pii]
AID - 10.1007/s11864-021-00863-y [doi]
PST - epublish
SO  - Curr Treat Options Oncol. 2021 Jun 29;22(8):73. doi: 10.1007/s11864-021-00863-y.